Adcomm votes yes on Leqembi full OK; Merck brings first IRA lawsuit; Special: LGBTQ+ leaders; Best-paying biopharma jobs; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
Amid this busy week with ASCO and BIO, you may have noticed a change in how our paywall operates. The gist of it: From now on, non-paying basic subscribers will get a limited amount of free articles each month, after which we’ll ask you to become a premium subscriber to access our stories. For premium subscribers, nothing will change. Your support has been crucial in growing our newsroom and we look forward to bringing more timely, unique and in-depth coverage.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.